SPG11 Antibody | 5015

SPG11 Antibody | 5015 | Gentaur UK, US & Europe Distribution

Host: Rabbit

Reactivity: Human, Mouse, Rat

Homology: N/A

Immunogen: SPG11 antibody was raised against a 15 amino acid synthetic peptide near the carboxy terminus of human SPG11.
The immunogen is located within amino acids 2360 - 2410 of SPG11.

Research Area: Apoptosis

Tested Application: E, WB, IHC-P

Application: SPG11 antibody can be used for detection of SPG11 by Western blot at 0.5 - 1 μg/mL. Antibody can also be used for immunohistochemistry starting at 2.5 μg/mL.
Antibody validated: Western Blot in mouse samples and Immunohistochemistry in mouse samples. All other applications and species not yet tested.

Specificiy: N/A

Positive Control 1: Cat. No. 1401 - Mouse Heart Tissue Lysate

Positive Control 2: N/A

Positive Control 3: N/A

Positive Control 4: N/A

Positive Control 5: N/A

Positive Control 6: N/A

Molecular Weight: N/A

Validation: N/A

Isoform: N/A

Purification: SPG11 Antibody is affinity chromatography purified via peptide column.

Clonality: Polyclonal

Clone: N/A

Isotype: IgG

Conjugate: Unconjugated

Physical State: Liquid

Buffer: SPG11 Antibody is supplied in PBS containing 0.02% sodium azide.

Concentration: 1 mg/mL

Storage Condition: SPG11 antibody can be stored at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

Alternate Name: SPG11 Antibody: KIAA1840, KIAA1840, Spatacsin, Colorectal carcinoma-associated protein

User Note: Optimal dilutions for each application to be determined by the researcher.

BACKGROUND: SPG11 Antibody: Hereditary spastic paraplegias (HSPs) are genetically and phenotypically heterogeneous disorders.  Spastic paraplegia with thinning of the corpus callosum (ARHSP-TCC) is a relatively frequent form of complicated hereditary spastic paraplegia (cHSP) in which mental retardation and muscle stiffness at onset are followed by slowly progressive paraparesis and cognitive deterioration. Mutations of the SPG11 gene encoding the spatacsin protein have been identified as a major cause of HSP-TCC. Spatacsin is a potential transmembrane protein that is phosphorylated upon DNA damage. It is expressed in all structures of the brain, with a high expression in the cerebellum. SPG11 mutations may occur more frequently in familial than sporadic forms of cHSP without TCC. Kjellin syndrome is found to be associated with mutations in not only the SPG15 gene but also SPG11 gene.  Recent studies show Parkinsonism may initiate SPG11-linked HSP TCC and that SPG11 may cause juvenile Parkinsonism.